{"url_path":"/sec/crvo/8-k/2026-06-18/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **         **Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-021038-index.html","accession_number":"0001437749-26-021038","cik":"0001053691","ticker":"CRVO","issuer_name":"CervoMed Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-021038-index.html","primary_entity_key":"0001053691","primary_entity_name":"CervoMed Inc."},"word_count":75,"has_tables":true,"body_markdown":"**Item 8.01**         **Other Events**\n\n \n\nOn June 16, 2026, CervoMed Inc. (the “Company”) received a notice of allowance from the United States Patent and Trademark Office related to a new patent protecting the Company’s use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies in patients with no substantial Alzheimer’s disease-like tau pathology, which is expected to provide intellectual property protection into 2042 (without giving effect to any potential patent term extension)."}